Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen. Issue 1 (6th May 2022)

• Record Type: Journal Article
• Authors: Ergenekon, Almala Pinar; Yilmaz Yegit, Cansu; Cenk, Muruvvet; Gokdemir, Yasemin; Erdem Eralp, Ela; Ozturk, Gulten; Unver, Olcay; Kenis Coskun, Ozge; Karadag Saygi, Evrim; Turkdogan, Dilsad; Karadag, Bulent
• Is Part Of: Pediatrics international. Volume 64:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-06
• Subjects: nusinersen -- respiratory follow up -- treatment; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/ped.15175
• Languages: English
• ISSNs: 1328-8067

Abstract

Abstract: Background: Respiratory failure is the leading cause of mortality in spinal muscular atrophy type 1 (SMA1) children. The current study aims to evaluate the effect of nusinersen treatment on respiratory outcome of the patients with SMA1. Methods: In this retrospective, single‐center study, 52 SMA1 patients treated with nusinersen were included in the analysis. Patients were divided into two groups based on their age at the time of their first nusinersen treatment (Group 1: ≤6 months, Group 2: >6 months). Respiratory outcome on the 180th day of treatment is defined as the type of ventilation support (spontaneous breathing, noninvasive ventilation (NIV), and tracheostomized or intubated on invasive mechanical ventilation). Demographic data, respiratory outcome, and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores were obtained from medical records. Results: On the 180th day of treatment, 46 of the 52 (88.4%) children were alive. Prevalence of the mortality was similar in both groups ( P = 0.65). The comparison of respiratory outcome in patients between group 1 and group 2 was as follows: spontaneous breathing, 7 (43.7%) versus 4 (13.3%) ( P = 0.03); NIV <16 h/day, 3 (18.7%) versus 4 (13.3%) ( P = 0.68); invasive mechanical ventilation, 6 (37.5%) versus 22 (73.3%) ( P = 0.01). There were no patients using NIV ≥16 h/day. There were significant improvements in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores of the patients at day 180 in comparison with the baseline ( P < 0.001). Conclusions: Early initiation of nusinersen treatment in SMA1 patients may alter the disease's natural course.